$IVVD

Invivyd, Inc.

Invivyd is a biopharmaceutical company that discovers, develops and commercializes monoclonal antibody therapies to prevent and treat serious viral infectious diseases. Its first authorized product, PEMGARDA, is an antibody for the pre-exposure prevention of COVID-19 in certain immunocompromised adults and adolescents. Invivyd is also developing VYD2311, an antibody candidate for COVID-19 prevention, and VBY329 for prevention of respiratory syncytial virus infections in neonates, infants and children. Its research also targets measles and other infectious diseases. Invivyd makes money by commercializing its products and developing antibody candidates for potential commercialization. It has directly hired sales, marketing, market access and medical affairs teams, including a field sales force to support PEMGARDA in the U.S. The company relies on outside partners and contractors for research, clinical trials, testing and manufacturing. Invivyd is headquartered in New Haven, Connecticut.

2
0
4

No SEC Form 4 filings for $IVVD in the last 30 days.

See all $IVVD insider activity →
Low

Invivyd stock maintains Buy rating at BTIG, $10 target

BTIG maintained a Buy rating and $10.00 price target on Invivyd Inc. (NASDAQ:IVVD), citing upcoming immunogenicity data from the DECLARATION trial. The stock is trading at $0.56, down 76% year-to-date. The company reported positive results from the LIBERTY trial for VYD2311, with strong safety and tolerability compared to an mRNA vaccine. Invivyd has a 92% gross profit margin but is burning through cash quickly.

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

IVVD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning IVVD (Invivyd, Inc.). Coverage has skewed bearish: 2 bullish, 0 neutral, and 4 bearish.

Recent IVVD coverage spans earnings, technology and financial news.

What's driving IVVD

AlphAI scores every news story that mentions IVVD with an AI model for sentiment and relevance, and aggregates insider trades from Invivyd, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IVVD

Score

Invivyd stock maintains Buy rating at BTIG, $10 target

BTIG maintained a Buy rating and $10.00 price target on Invivyd Inc. (NASDAQ:IVVD), citing upcoming immunogenicity data from the DECLARATION trial. The stock is trading at $0.56, down 76% year-to-date. The company reported positive results from the LIBERTY trial for VYD2311, with strong safety and tolerability compared to an mRNA vaccine. Invivyd has a 92% gross profit margin but is burning through cash quickly.

$IVVDHighEarnings

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.

$IVVDMedAI 9/10Clinical / regulatory· topline data

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine…

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing

$IVVDMedAI 8/10

Invivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial

Invivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.

$IVVDMedExec change· appointed

Invivyd, Inc. (IVVD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY • Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate s

$IVVDMedEarnings

Invivyd Reports Second Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme

Related tickers